Search Result
Results for "
collagen deposition
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
| Cat. No. |
상품명 |
Target |
연구분야 |
Chemical Structure |
-
- HY-B0166
-
-
-
- HY-B0166A
-
-
-
- HY-P0170
-
TB500
1 Publications Verification
|
Drug Derivative
Akt
P2X Receptor
|
Inflammation/Immunology
|
|
TB500 is a synthetic version of an active region of thymosin β4. TB500 exhibits anti-fibrotic and wound healing activities by inhibiting the Akt signaling pathway and binding to actin. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation .
|
-
-
- HY-B0166R
-
|
L-Ascorbate (Standard); Vitamin C (Standard)
|
Reference Standards
Reactive Oxygen Species (ROS)
Calcium Channel
Apoptosis
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
|
L-Ascorbic acid (Standard) is the analytical standard of L-Ascorbic acid. This product is intended for research and analytical applications. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
-
- HY-107588
-
TC-I 15
2 Publications Verification
|
Integrin
|
Cardiovascular Disease
|
|
TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
|
-
-
- HY-128483
-
|
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
-
- HY-149136
-
|
|
Integrin
TGF-beta/Smad
|
Inflammation/Immunology
|
|
MORF-627 is a highly selective, orally active integrin αvβ6 inhibitor. By blocking TGF-β1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-β. MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety .
|
-
-
- HY-N0912
-
-
-
- HY-40136
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
|
cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
|
-
-
- HY-B0166S
-
-
-
- HY-N6857
-
|
|
AP-1
NF-κB
p38 MAPK
ERK
JNK
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Armepavine, found in Nelumbo nucifera, is an orally active NF-κB inhibitor. Armepavine attenuates expression of p-p65, α-SMA, p-JNK1/2, p-ERK1/2, p-p38α stimulated by TNF-α and LPS. Armepavine suppresses NF-κB nuclear translocation, IκBα phosphorylation, and collagen deposition. Armepavine can be used for the research of hepatic fibrosis and leukemia .
|
-
-
- HY-P99047
-
|
AB 0024; GS 6624
|
Monoamine Oxidase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression and attenuates extracellular matrix changes. Simtuzumab reduces myocardial fibrosis and prevents cardiac dysfunction. Simtuzumab lowers Myh7 and Nppa gene expression, reduces contraction heterogeneity, and cuts COL1A1 deposition. Simtuzumab can be used for the research of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis .
|
-
-
- HY-149662
-
|
|
Calcium Channel
ATP Synthase
Myosin
|
Cardiovascular Disease
|
|
TMDJ-035 is a high-affinity, selective RyR2 inhibitor with an EC50 of 0.0130 μM. TMDJ-035 reduces RyR2 protein expression without affecting action potential-induced Ca 2+ transients. TMDJ-035 decreases ATP content and intracellular Ca 2+ levels. TMDJ-035 inhibits arrhythmias in a CPVT mouse model carrying mutant RyR2s. TMDJ-035 has no effect on electrocardiogram parameters or cardiac systolic function. TMDJ-035 exacerbates heart failure in mouse myocardial infarction models and hypoxic cardiomyocytes by altering cardiac function, causing tissue damage, promoting inflammatory infiltration, collagen deposition, and changes in Myosin heavy chain/actin expression. TMDJ-035 can be used in studies related to heart failure, catecholaminergic polymorphic ventricular tachycardia, and arrhythmias .
|
-
-
- HY-N0008
-
|
|
Wnt
p38 MAPK
mTOR
Keap1-Nrf2
TGF-β Receptor
|
Neurological Disease
Metabolic Disease
|
|
Orcinol glucoside is an orally active, blood-brain barrier permeable osteoblast proliferation promoter that targets the Nrf2/Keap1, mTOR and p38 signaling pathways. Orcinol glucoside promotes Nrf2 nuclear translocation, upregulates antioxidant enzyme levels, enhances the phosphorylation of mTOR and p70S6K, and inhibits the enzymatic activity of HAS2 as well as the nuclear translocation of GR. Orcinol glucoside also alleviates oxidative stress, inhibits autophagic flux, osteoclastogenesis and TGF-β1-induced M2 polarization, while reducing collagen deposition and effectively promoting the proliferation, differentiation and mineralization of osteoblasts. Orcinol glucoside also exhibits anti-pulmonary fibrosis, anxiolytic and antidepressant activities. Orcinol glucoside can be used in the research of senile and glucocorticoid-induced osteoporosis, idiopathic pulmonary fibrosis (IPF), anxiety and other related diseases .
|
-
-
- HY-114557
-
|
3,5-Diiodo-L-thyronine
|
JNK
NF-κB
Sirtuin
PGC-1α
COX
TGF-β Receptor
Collagen
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
|
-
-
- HY-B0166S8
-
|
L-Ascorbate-1; Vitamin C-13C6-1
|
Isotope-Labeled Compounds
Endogenous Metabolite
Reactive Oxygen Species (ROS)
Calcium Channel
Apoptosis
|
Cancer
|
|
L-Ascorbic acid- 13C6-1 (L-Ascorbate-1; Vitamin C- 13C6-1) is a 13C labeled L-Ascorbic acid (HY-B0166) . L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
-
- HY-151499A
-
|
|
Monoamine Oxidase
|
Inflammation/Immunology
|
|
PXS-6302 hydrochloride is an irreversible lysyl oxidase inhibitor with IC50s of 3.7 μM (Bovine LOX), 3.4 μM (rh LOXL1), 0.4 μM (rh LOXL2), 1.5 μM (rh LOXL3), 0.3 μM (rh LOXL4), respectively. PXS-6302 hydrochloride has readily skin penetrability, reduces collagen deposition and significantly improves scar appearance .
|
-
-
- HY-P5243
-
|
AHK-Cu
|
Others
Bcl-2 Family
|
Others
|
|
Copper tripeptide-3 (AHK-Cu) is a bioactive peptide with promotion of hair growth effect. Copper tripeptide-3 increases dermal cell proliferation and viability while increasing the deposition of collagen to renew the extracellular matrix. Copper tripeptide-3 stimulates the elongation of human hair follicles and proliferation of dermal papilla cells .
|
-
-
- HY-171955
-
|
|
Lipoxygenase
Apoptosis
Reactive Oxygen Species (ROS)
FAK
|
Cancer
|
|
LXG6403 is an orally active and irreversible LOX inhibitor (IC50 = 1.3 μM). LXG6403 is ~3.5-fold more specific for LOX than LOXL2 and does not inhibit LOXL1. LXG6403 inhibits FAK signaling and induces ROS generation and DNA damage, leading to G1 arrest and apoptosis in chemoresistant triple-negative breast cancer (TNBC) cell lines. LXG6403 alters the extracellular matrix (ECM) and collagen structure, reducing collagen cross-linking and deposition, thereby increasing drug penetration and reducing tumor stiffness. LXG6403 overcomes Doxorubicin (HY-15142) resistance in chemoresistant TNBC PDX in vivo and can be used to study high-stiffness resistant tumors .
|
-
-
- HY-174400
-
|
|
SGLT
SOD
Na+/H+ Exchanger (NHE)
Autophagy
|
Cardiovascular Disease
|
|
SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice .
|
-
-
- HY-158226
-
|
ElaMA
|
Biochemical Assay Reagents
|
Others
|
Elastin Methacrylated (ElaMA) elastin recruits and modulates innate immune cells and accelerates angiogenesis at the wound site, thereby improving wound regeneration. Elastin Methacrylated attracts large numbers of neutrophils and primarily M2 macrophages to the wound and induces their penetration into the hydrogel. Elastin Methacrylated has excellent immunomodulatory effects, leading to superior angiogenesis, collagen deposition and dermal regeneration . Elastin Methacrylated needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity. Application: cell culture, biological 3D printing, tissue engineering, etc.
|
-
-
- HY-P5832
-
|
|
TGF-beta/Smad
RUNX
|
Metabolic Disease
|
|
BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research .
|
-
-
- HY-151499
-
|
|
Monoamine Oxidase
|
Others
|
|
PXS-6302 is an irreversible lysyl oxidase inhibitor with IC50s of 3.7 μM (Bovine LOX), 3.4 μM (rh LOXL1), 0.4 μM (rh LOXL2), 1.5 μM (rh LOXL3), 0.3 μM (rh LOXL4), respectively. PXS-6302 has readily skin penetrability, reduces collagen deposition and significantly improves scar appearance .
|
-
-
- HY-B0166S1
-
-
-
- HY-151498A
-
|
|
Monoamine Oxidase
|
Others
|
|
PXS-4787 hydrochloride is a specific and effective pan-LOX (lysyl oxidase) inhibitor for abolishing lysyl oxidase activity. PXS-4787 hydrochloride inhibits LOX with IC50s of 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), 0.2 μM (rh LOXL4), respectively. PXS-4787 hydrochloride reduces deposition and crosslinking of collagen I secreted by human fibroblasts .
|
-
-
- HY-178821
-
|
|
ROCK
TGF-beta/Smad
STAT
|
Inflammation/Immunology
|
|
ROCK2-IN-12 (Compound A25) is a selective ROCK2 inhibitor with an IC50 of 7.0 nM for ROCK2 over ROCK1. ROCK2-IN-12 has potent antifibrotic effects via the TGF-β/Smad and ROCK2/STAT3 signaling pathways. ROCK2-IN-12 significantly reduces collagen deposition and reverses fibrotic progression in Bleomycin (HY-108345)-induced pulmonary fibrosis (PF) mouse models. ROCK2-IN-12 can be used for lung diseases like pulmonary fibrosis research .
|
-
-
- HY-151498
-
|
|
Monoamine Oxidase
|
Others
|
|
PXS-4787 is a specific and effective pan-LOX (lysyl oxidase) inhibitor for abolishing lysyl oxidase activity. PXS-4787 inhibits LOX with IC50s of 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), 0.2 μM (rh LOXL4), respectively .
|
-
-
- HY-B0166GL
-
|
L-Ascorbate (GMP Like); Vitamin C (GMP Like)
|
Reactive Oxygen Species (ROS)
Apoptosis
Calcium Channel
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
|
L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
-
- HY-145358
-
|
|
PI3K
|
Cancer
|
|
FAP-PI3KI1 is a fibroblast-activated protein (FAP)-targeted PI3K inhibitor that selectively targets FAP-expressing human idiopathic pulmonary fibrosis (IPF) cells and effectively inhibits collagen synthesis and reduces collagen deposition .
|
-
-
- HY-146205
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
ATX inhibitor 18 is a potent ATX inhibitor with an IC50 value of 24.2 nM. ATX inhibitor 18 shows antiproliferative activity and anti-fibrosis activity. ATX inhibitor 18 suppresses collagen deposition in TGF-β-mediated cardiac fibrosis .
|
-
-
- HY-40136S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
|
cis-4-Hydroxy-L-proline-d3 is the deuterium labeled cis-4-Hydroxy-L-proline (HY-40136). cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
|
-
-
- HY-N10359
-
|
|
NOD-like Receptor (NLR)
Caspase
Akt
GSK-3
β-catenin
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Isoandrographolide is an orally active NLRP3 inflammasome inhibitor and AKT/GSK-3β/β-catenin pathway inhibitor. Isoandrographolide inhibits the expression of NLRP3, ASC, and caspase-1, and reduces the levels of phosphorylated AKT, phosphorylated GSK-3β, and β-catenin. Isoandrographolide alleviates inflammatory responses, reduces collagen deposition, suppresses epithelial-mesenchymal transition (EMT), induces differentiation of leukemia cells, inhibits the growth of leukemia cells, protects lung and kidney tissues, regulates cytokine levels, and also exhibits hepatoprotective effects. Isoandrographolide can be used in studies related to silicosis, murine myeloid leukemia, renal tubulointerstitial fibrosis, and non-alcoholic fatty liver disease .
|
-
-
- HY-110246
-
|
|
Formyl Peptide Receptor (FPR)
|
Inflammation/Immunology
|
|
Quin C1 is a highly specific and potent agonist for formyl peptide receptor 2 (FPR2/ALX). Quin-C1 significantly reduces the neutrophil and lymphocyte counts in BALF, diminishes expression of TNF-α, IL-1β, KC, and TGF-β1, and decreases collagen deposition in lung tissue. Quin C1 has the potential for the research of lung injury .
|
-
-
- HY-B0166AR
-
|
Sodium ascorbate (Standard); Sodium L-ascorbate (Standard); Vitamin C sodium salt (Standard)
|
Reference Standards
Calcium Channel
Reactive Oxygen Species (ROS)
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
L-Ascorbic acid (sodium salt) (Standard) is the analytical standard of L-Ascorbic acid (sodium salt). This product is intended for research and analytical applications. L-Ascorbic acid sodium salt (Sodium ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid sodium salt is also a collagen deposition enhancer and an elastogenesis inhibitor .
|
-
-
- HY-175662
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
TGF-β/Smad-IN-2 is an orally active TGF-β/Smad inhibitor. TGF-β/Smad-IN-2 inhibits TGF-β-induced fibroblast-to-myofibroblast differentiation and collagen deposition, with an IC50 value of 102 μM for collagen reduction in LL29 cells. TGF-β/Smad-IN-2 exerts its effects through modulation
of the SMAD3/SMAD7 signaling pathway. TGF-β/Smad-IN-2 reduces lung index in pulmonary fibrosis mice. TGF-β/Smad-IN-2 can be used for the study of pulmonary fibrosis .
|
-
-
- HY-B0166E
-
|
L-Ascorbate magnesium; Vitamin C magnesium
|
Reactive Oxygen Species (ROS)
Calcium Channel
Apoptosis
Endogenous Metabolite
|
Neurological Disease
|
|
L-Ascorbic acid (L-Ascorbate) magnesium, an electron donor, is an endogenous antioxidant. L-Ascorbic acid selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition promoter and elastin production inhibitor. L-Ascorbic acid exhibits anticancer effects by generating reactive oxygen species (ROS) and selectively damaging cancer cells .
|
-
-
- HY-141436
-
|
Sucrose octasulfate potassium
|
MMP
Biochemical Assay Reagents
|
Cardiovascular Disease
Metabolic Disease
|
|
Sucrosofate potassium (Sucrose octasulfate potassium) is a wound healing promoter. Sucrosofate potassium inhibits MMP, promotes angiogenesis and improves microcirculation. Sucrosofate potassium causes mild skin irritation. Sucrosofate potassium can be used to prepare p (MMA-co-AM)/PVA@PSO hydrogels. Sucrosofate potassium is applicable to research related to diabetic wounds .
|
-
-
- HY-179042
-
|
|
TGF-beta/Smad
p38 MAPK
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
TGF-β/Smad-IN-3 (Compound 4w) is an effective TGF-β/Smad inhibitor. TGF-β/Smad-IN-3 exerts anti-pulmonary fibrosis activity by simultaneously inhibiting the TGF-β/Smad and MAPK signaling pathways. TGF-β/Smad-IN-3 significantly inhibits collagen deposition induced by TGF-β1, with its IC50 value being 3.21 μM. TGF-β/Smad-IN-3 has an IC₅₀ of 46.77 nM for the autocrine motility factor (ATX). TGF-β/Smad-IN-3 significantly reduces the expression levels of α-SMA, COL1A1 and FN in TGF-β1-induced CCC-HPF-1 cells, and effectively inhibited TGF-β1-induced cell migration. TGF-β/Smad-IN-3 can be used for the study of pulmonary fibrosis .
|
-
-
- HY-137492
-
|
|
Drug Derivative
|
Metabolic Disease
|
|
16,16-Dimethyl-PGE2-4-(4-acetamidobenzamido)phenyl ester is a derivative of 16,16-Dimethyl-PGE2 (HY-106420). 16,16-Dimethyl-PGE2-4-(4-acetamidobenzamido)phenyl ester is a prodrug for 16,16-Dimethyl-PGE2 .
|
-
-
- HY-173483
-
|
|
Phosphodiesterase (PDE)
ERK
JNK
p38 MAPK
|
Inflammation/Immunology
|
|
ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. ATX inhibitor 26 inhibits cell migration and collagen gel contraction. ATX inhibitor 26 has significant anti-fibrotic effects, reducing collagen deposition in a Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis model .
|
-
-
- HY-145855
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
J-1063 is a potent, selective and orally active ALK5 inhibitor with an IC50 of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis .
|
-
-
- HY-175537
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
ATX-IN-3 is an orally active autotaxin (ATX) inhibitor with an IC50 of 46 nM. ATX-IN-3 certainly reduces collagen deposition and ameliorates lung fibrosis in the pulmonary fibrosis mouse model. ATX-IN-3 has good metabolic stability and drug-like properties. ATX-IN-3 can used for the study of idiopathic pulmonary fibrosis (IFP) .
|
-
-
- HY-163507
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
ALK5-IN-79 (compound 57) is an ALK inhibitor with anticancer activity, by blocking TGF-β1/SMAD signaling pathway. ALK5-IN-79 attenuates the production of extracellular matrix (ECM) and deposition of collagen. ALK5-IN-79 exhibits adequate pharmacokinetic (PK) properties and good in vivo tolerance.
|
-
-
- HY-170839
-
|
|
TRP Channel
|
Inflammation/Immunology
|
|
TRPV1-IN-3 (compound 14) is a TRPV1 inhibitor that can be used for the research of idiopathic pulmonary fibrosis. TRPV1-IN-3 affects the expression of fibrosis markers collagen I and α-SMA by inhibiting the TGF-β/Smads and MAPK pathways, thereby exerting antifibrotic activity in vitro (IC50=0.51 μM). TRPV1-IN-3 significantly inhibits collagen deposition in lung tissue, improves the alveolar structure, and also increases the survival rate of mice with pulmonary fibrosis induced by Bleomycin (HY-108345) .
|
-
-
- HY-149205
-
|
|
PI3K
ERK
|
Inflammation/Immunology
|
|
CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy .
|
-
-
- HY-170765
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
ATX-IN-1 (compound 35) is an inhibitor of ATX (IC50=0.7 nM) with anti-inflammatory activity. ATX-IN-1 can inhibit TGF-β/Smad pathway and reduce collagen deposition to alleviate Bleomycin (HY-108345)-induced fibrosis in mice. ATX-IN-1 has good oral bioavailability (F=69.5%) and particle stability .
|
-
-
- HY-N0912R
-
|
|
Reference Standards
Reactive Oxygen Species (ROS)
|
Metabolic Disease
Inflammation/Immunology
|
|
Rehmannioside D (Standard) is the analytical standard of Rehmannioside D (HY-N0912). This product is intended for research and analytical applications. Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis .
|
-
-
- HY-40136R
-
|
|
Reference Standards
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
|
cis-4-Hydroxy-L-proline (Standard) is the analytical standard of cis-4-Hydroxy-L-proline (HY-40136). This product is intended for research and analytical applications. cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
|
-
-
- HY-133794R
-
|
|
Reference Standards
Drug Metabolite
|
Cancer
|
|
L-Ascorbic acid (GMP Like) (Standard) is the analytical standard of L-Ascorbic acid (GMP Like). This product is intended for research and analytical applications. L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
-
- HY-128483R
-
|
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
Reference Standards
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
- HY-114557R
-
|
3,5-Diiodo-L-thyronine (Standard)
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
|
NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
|
-
- HY-182287
-
|
|
Reactive Oxygen Species (ROS)
NOD-like Receptor (NLR)
|
Metabolic Disease
|
|
PRDX1-IN-4 is a PRDX1 inhibitor with an IC50 of 122 nM against human targets and high subtype selectivity. PRDX1-IN-4 covalently binds to PRDX1 to promote ROS accumulation. PRDX1-IN-4 inhibits NLRP3 inflammasome activation, blocks hepatic stellate cell activation and reduces collagen deposition. PRDX1-IN-4 induces apoptosis in activated hepatic stellate cells. PRDX1-IN-4 has good safety profile, with no significant body weight loss or hepatotoxicity observed in mice at a dose of 20 mg/kg. PRDX1-IN-4 ameliorates CCl4-induced liver injury and liver fibrosis in mice at a dose of 1 mg/kg. PRDX1-IN-4 can be used for the research of liver fibrosis .
|
-
- HY-181741
-
|
|
Cathepsin
|
Inflammation/Immunology
|
|
PI3K-001 is a cathepsin B-responsive prodrug and antifibrotic agent. PI3K-001 undergoes cathepsin B-mediated cleavage of the Val-Ala linker in fibrotic lung lesions to release an active PI3K inhibitor payload, while it remains stable in healthy tissues. PI3K-001 improves collagen deposition, tissue collapse and alveolar injury in fibrotic lung tissues. PI3K-001 is applicable for the research of pulmonary fibrosis .
|
-
- HY-181931
-
|
|
Phosphodiesterase (PDE)
p38 MAPK
LPL Receptor
ERK
JNK
|
Inflammation/Immunology
|
|
Autotaxin-IN-8 (Compound 14E) is an orally active Autotaxin inhibitor with an IC50 of 14.2 nM against hAutotaxin. Autotaxin-IN-8 inhibits Autotaxin activity, MAPK activation, LPAR1 and p-ERK1/2. Autotaxin-IN-8 reduces the phosphorylation levels of JNK and p38. Autotaxin-IN-8 decreases collagen deposition in a mouse model of pulmonary fibrosis. Autotaxin-IN-8 can be used in research related to pulmonary fibrosis .
|
-
- HY-107588R
-
|
|
Reference Standards
Integrin
|
Cardiovascular Disease
|
|
TC-I 15 (Standard) is the analytical standard of TC-I 15 (HY-107588). This product is intended for research and analytical applications. TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
|
-
- HY-181431
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
PXS 64, a mannose-6-phosphate (M6P) analogue. a lipophilic prodrug of PXS 25 (HY-181430). PXS 64 is an effective anti-fibrotic agent by inhibiting the activation of latent TGF-β1. PXS64, inhibits fibrosis via TGF-β1 pathway in human lung fibroblasts. PXS 64 reduces TGFβ-mediated collagen IV, fibronectin, MCP-1, and phospho-smad2 expression in kidney cells. PXS 64 reduces collagen deposition in dermal scar fibroblasts. PXS 64 can be used for the research of chronic kidney disease, idiopathic pulmonary fibrosis, scarring .
|
-
- HY-184001
-
|
|
RIP kinase
Akt
PI3K
NF-κB
Interleukin Related
Necroptosis
|
Metabolic Disease
|
|
LT-1339-553 is a selective, orally active RIPK1 inhibitor with IC50 values of 4.32, 95.74 and 84.33 nM against RIPK1, RIPK2 and RIPK3, respectively. LT-1339-553 exerts anti-necroptotic activity by inhibiting the AKT/PI3K/NF-κB pathway and the IL-17 pathway. LT-1339-553 reduces liver injury, inflammatory responses and collagen deposition. LT-1339-553 can be used in studies related to schistosomiasis-induced liver fibrosis .
|
-
- HY-P11467
-
|
|
Bacterial
p38 MAPK
NF-κB
PERK
JNK
|
Cardiovascular Disease
Infection
|
|
Gy-CATH is an anionic antimicrobial peptide. Gy-CATH activates MAPK and NF-κB signaling pathways (elevated levels of phospho-ERK, -p38, -JNK, -p65, and -IκBα). Gy-CATH upregulates the expression levels of three physiological anticoagulant pathways. Gy-CATH inhibits ADP-, Collagen-, and PMA-induced platelet aggregation. Gy-CATH has no direct antimicrobial activity, but shows significant preventive abilities against mice infected with Staphylococcus aureus, Escherichia coli, and Methicillin (HY-121544)-resistant Staphylococcus aureus. Gy-CATH exhibits potent immunomodulatory activity, enhancing macrophage-and neutrophil-mediated bactericidal functions. Gy-CATH significantly reduces the extent of pulmonary fibrin deposition and prevents thrombosis in mice .
|
-
- HY-180581
-
|
|
Monoamine Oxidase
Guanylate Cyclase
|
Cardiovascular Disease
|
|
LOXL2/sGC modulator-1 (Compound 11k) is a LOXL2 inhibitor (IC₅₀ = 0.13 μM) and an sGC activator. LOXL2/sGC modulator-1 shows good selectivity for LOX (IC₅₀ > 45.9 μM) and LOXL3 (IC₅₀ = 1.30 μM). LOXL2/sGC modulator-1 significantly increases intracellular cGMP levels in the presence of the gGC inhibitor ODQ (HY-101255). LOXL2/sGC modulator-1 significantly inhibits hypoxia-induced collagen deposition and cross-linking, while promoting vasodilation. LOXL2/sGC modulator-1 can be used for the study of pulmonary arterial hypertension .
|
-
- HY-P992108
-
|
RELAX10
|
RXFP Receptor
Akt
NO Synthase
VEGFR
|
Cardiovascular Disease
|
|
Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .
|
-
- HY-180556
-
|
|
mTOR
PI3K
|
Inflammation/Immunology
|
PI3K/mTOR-IN-20 is a selective dual PI3K/mTOR inhibitor. PI3K/mTOR-IN-20 demonstrates nanomolar antiproliferative effects with IC50s of 0.380 and 0.090 μM for MRC-5 and Mlg2908 cells. PI3K/mTOR-IN-20 reduces Ashcroft scores, hydroxyproline content, collagen deposition, and downregulates fibrosis-related proteins, while restoring lung architecture in a Bleomycin-induced pulmonary fibrosis model. PI3K/mTOR-IN-20 shows a favorable safety profile with steady weight recovery and no distinct liver or kidney toxicity. PI3K/mTOR-IN-20 can be used for fetal lung fibroblasts research .
|
-
- HY-P992076
-
|
|
TGF-β Receptor
TGF-beta/Smad
Cholinesterase (ChE)
Fungal
|
Infection
Cancer
|
Anti-Candida auris β-1,3-glucans Antibody (2G8) is an antibody targeting Candida auris β-1,3-glucans, and also acts as an inhibitor of AChE and TGF-β receptor 2. Anti-Candida auris β-1,3-glucans Antibody (2G8) also targets fungal cell wall components, effectively inhibits fungal growth and interferes with capsule formation, thereby significantly reducing the fungal load in mouse tissues. Anti-Candida auris β-1,3-glucans Antibody (2G8) not only blocks TGF-β receptor binding to inhibit the Smad signaling pathway, reduces fibroblast activation and collagen deposition, but also induces epithelial differentiation of tumor cells and reduces pancreatic tumor metastasis. Anti-Candida auris β-1,3-glucans Antibody (2G8) specifically binds to the conserved N-linked glycoepitope on AChE to inhibit its activity without interfering with BChE, and can be used in studies of cryptococcosis and related tumor mechanisms .The isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-B0166GL
-
|
L-Ascorbate (GMP Like); Vitamin C (GMP Like)
|
Fluorescent Dyes
|
|
L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
- HY-158226
-
|
ElaMA
|
Biochemical Assay Reagents
|
Elastin Methacrylated (ElaMA) elastin recruits and modulates innate immune cells and accelerates angiogenesis at the wound site, thereby improving wound regeneration. Elastin Methacrylated attracts large numbers of neutrophils and primarily M2 macrophages to the wound and induces their penetration into the hydrogel. Elastin Methacrylated has excellent immunomodulatory effects, leading to superior angiogenesis, collagen deposition and dermal regeneration . Elastin Methacrylated needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity. Application: cell culture, biological 3D printing, tissue engineering, etc.
|
-
- HY-B0166GL
-
|
L-Ascorbate (GMP Like); Vitamin C (GMP Like)
|
Biochemical Assay Reagents
|
|
L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
- HY-B0166E
-
|
L-Ascorbate magnesium; Vitamin C magnesium
|
Biochemical Assay Reagents
|
|
L-Ascorbic acid (L-Ascorbate) magnesium, an electron donor, is an endogenous antioxidant. L-Ascorbic acid selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition promoter and elastin production inhibitor. L-Ascorbic acid exhibits anticancer effects by generating reactive oxygen species (ROS) and selectively damaging cancer cells .
|
| Cat. No. |
상품명 |
Target |
Research Area |
-
- HY-P0170
-
TB500
1 Publications Verification
|
Drug Derivative
Akt
P2X Receptor
|
Inflammation/Immunology
|
|
TB500 is a synthetic version of an active region of thymosin β4. TB500 exhibits anti-fibrotic and wound healing activities by inhibiting the Akt signaling pathway and binding to actin. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decrease inflammation .
|
-
- HY-P5284
-
|
|
Peptides
|
Others
|
|
RALA peptide is a cationic amphiphilic delivery agent targeting cell membranes, which forms nanoparticles through electrostatic interactions with anionic drugs. RALA peptide has pH-responsive binding properties, which can enhance the α-helical conformation in an acidic environment and destroy the endosomal membrane, promote the release of drugs into the cytoplasm, and exert efficient intracellular delivery activity. RALA peptide can be used in cancer research (enhancing the activity of bisphosphonates against prostate cancer and breast cancer cells) and bone tissue engineering (promoting osteoblast collagen deposition and extracellular matrix mineralization) .
|
-
- HY-P5243
-
|
AHK-Cu
|
Peptides
Bcl-2 Family
|
Others
|
|
Copper tripeptide-3 (AHK-Cu) is a bioactive peptide with promotion of hair growth effect. Copper tripeptide-3 increases dermal cell proliferation and viability while increasing the deposition of collagen to renew the extracellular matrix. Copper tripeptide-3 stimulates the elongation of human hair follicles and proliferation of dermal papilla cells .
|
-
- HY-P5832
-
|
|
TGF-beta/Smad
RUNX
|
Metabolic Disease
|
|
BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research .
|
-
- HY-149205
-
|
|
PI3K
ERK
|
Inflammation/Immunology
|
|
CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy .
|
-
- HY-P1711
-
|
|
Peptides
|
Cardiovascular Disease
|
|
L 366763 is a potent peptide that acts as a fibrinogen receptor antagonist, preventing collagen-induced platelet aggregation and adhesion. L 366763 inhibits platelet deposition and maintains blood flow in a baboon thrombosis model, significantly prolonging bleeding time. L 366763 has antithrombotic efficacy, whereas recombinant LAPP does not have the same effect .
|
-
- HY-P11467
-
|
|
Bacterial
p38 MAPK
NF-κB
PERK
JNK
|
Cardiovascular Disease
Infection
|
|
Gy-CATH is an anionic antimicrobial peptide. Gy-CATH activates MAPK and NF-κB signaling pathways (elevated levels of phospho-ERK, -p38, -JNK, -p65, and -IκBα). Gy-CATH upregulates the expression levels of three physiological anticoagulant pathways. Gy-CATH inhibits ADP-, Collagen-, and PMA-induced platelet aggregation. Gy-CATH has no direct antimicrobial activity, but shows significant preventive abilities against mice infected with Staphylococcus aureus, Escherichia coli, and Methicillin (HY-121544)-resistant Staphylococcus aureus. Gy-CATH exhibits potent immunomodulatory activity, enhancing macrophage-and neutrophil-mediated bactericidal functions. Gy-CATH significantly reduces the extent of pulmonary fibrin deposition and prevents thrombosis in mice .
|
-
- HY-K0610
-
|
|
|
MCE Sirius Red Staining Kit consists of hematoxylin staining solution and Sirius Red staining solution and is mainly used to observe abnormal collagen deposition or fibrosis in various pathological tissues. Under a conventional light microscope, collagen fibers in tissues such as the heart and blood vessels appear red. Under polarized light microscopy, this method is useful for the classification and evaluation of different types of fibrotic lesions.
|
| Cat. No. |
상품명 |
Target |
Research Area |
Image |
-
- HY-P99047
-
|
AB 0024; GS 6624
|
Monoamine Oxidase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression and attenuates extracellular matrix changes. Simtuzumab reduces myocardial fibrosis and prevents cardiac dysfunction. Simtuzumab lowers Myh7 and Nppa gene expression, reduces contraction heterogeneity, and cuts COL1A1 deposition. Simtuzumab can be used for the research of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis .
|
-
(5)
-
- HY-P992108
-
|
RELAX10
|
RXFP Receptor
Akt
NO Synthase
VEGFR
|
Cardiovascular Disease
|
|
Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .
|
-
(5)
-
- HY-P992076
-
|
|
TGF-β Receptor
TGF-beta/Smad
Cholinesterase (ChE)
Fungal
|
Infection
Cancer
|
Anti-Candida auris β-1,3-glucans Antibody (2G8) is an antibody targeting Candida auris β-1,3-glucans, and also acts as an inhibitor of AChE and TGF-β receptor 2. Anti-Candida auris β-1,3-glucans Antibody (2G8) also targets fungal cell wall components, effectively inhibits fungal growth and interferes with capsule formation, thereby significantly reducing the fungal load in mouse tissues. Anti-Candida auris β-1,3-glucans Antibody (2G8) not only blocks TGF-β receptor binding to inhibit the Smad signaling pathway, reduces fibroblast activation and collagen deposition, but also induces epithelial differentiation of tumor cells and reduces pancreatic tumor metastasis. Anti-Candida auris β-1,3-glucans Antibody (2G8) specifically binds to the conserved N-linked glycoepitope on AChE to inhibit its activity without interfering with BChE, and can be used in studies of cryptococcosis and related tumor mechanisms .The isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
| Cat. No. |
상품명 |
Category |
Target |
Chemical Structure |
-
- HY-B0166
-
-
-
- HY-B0166A
-
-
-
- HY-B0166R
-
-
-
- HY-128483
-
|
|
Infection
Microorganisms
Classification of Application Fields
Ketones, Aldehydes, Acids
Disease Research Fields
Source Classification
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
|
|
Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
-
- HY-N0912
-
-
-
- HY-40136
-
-
-
- HY-N6857
-
-
-
- HY-N0008
-
|
|
Curculigo orchioides Gaertn.
Structural Classification
Monophenols
Phenols
Plants
Amaryllidaceae
Source Classification
|
Wnt
p38 MAPK
mTOR
Keap1-Nrf2
TGF-β Receptor
|
|
Orcinol glucoside is an orally active, blood-brain barrier permeable osteoblast proliferation promoter that targets the Nrf2/Keap1, mTOR and p38 signaling pathways. Orcinol glucoside promotes Nrf2 nuclear translocation, upregulates antioxidant enzyme levels, enhances the phosphorylation of mTOR and p70S6K, and inhibits the enzymatic activity of HAS2 as well as the nuclear translocation of GR. Orcinol glucoside also alleviates oxidative stress, inhibits autophagic flux, osteoclastogenesis and TGF-β1-induced M2 polarization, while reducing collagen deposition and effectively promoting the proliferation, differentiation and mineralization of osteoblasts. Orcinol glucoside also exhibits anti-pulmonary fibrosis, anxiolytic and antidepressant activities. Orcinol glucoside can be used in the research of senile and glucocorticoid-induced osteoporosis, idiopathic pulmonary fibrosis (IPF), anxiety and other related diseases .
|
-
-
- HY-114557
-
|
3,5-Diiodo-L-thyronine
|
Structural Classification
Monophenols
Classification of Application Fields
Ketones, Aldehydes, Acids
Phenols
Metabolic Disease
Endogenous metabolite
Disease Research Fields
Source Classification
|
JNK
NF-κB
Sirtuin
PGC-1α
COX
TGF-β Receptor
Collagen
|
|
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
|
-
-
- HY-N10359
-
|
|
Acanthaceae
Classification of Application Fields
Simsia foetida (Cav.) S.F.Blake
Terpenoids
Diterpenoids
Plants
Inflammation/Immunology
Disease Research Fields
Source Classification
|
NOD-like Receptor (NLR)
Caspase
Akt
GSK-3
β-catenin
|
|
Isoandrographolide is an orally active NLRP3 inflammasome inhibitor and AKT/GSK-3β/β-catenin pathway inhibitor. Isoandrographolide inhibits the expression of NLRP3, ASC, and caspase-1, and reduces the levels of phosphorylated AKT, phosphorylated GSK-3β, and β-catenin. Isoandrographolide alleviates inflammatory responses, reduces collagen deposition, suppresses epithelial-mesenchymal transition (EMT), induces differentiation of leukemia cells, inhibits the growth of leukemia cells, protects lung and kidney tissues, regulates cytokine levels, and also exhibits hepatoprotective effects. Isoandrographolide can be used in studies related to silicosis, murine myeloid leukemia, renal tubulointerstitial fibrosis, and non-alcoholic fatty liver disease .
|
-
-
- HY-B0166AR
-
-
-
- HY-N0912R
-
-
-
- HY-40136R
-
-
-
- HY-128483R
-
|
|
Structural Classification
Microorganisms
Ketones, Aldehydes, Acids
Source Classification
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
Reference Standards
|
|
Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
-
- HY-114557R
-
|
3,5-Diiodo-L-thyronine (Standard)
|
Structural Classification
Monophenols
Ketones, Aldehydes, Acids
Phenols
Endogenous metabolite
Source Classification
|
Reference Standards
Endogenous Metabolite
|
|
NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
|
-
| Cat. No. |
상품명 |
Chemical Structure |
-
- HY-B0166S
-
|
|
|
L-Ascorbic acid- 13C6 is the 13C-labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
-
- HY-B0166S8
-
|
|
|
L-Ascorbic acid- 13C6-1 (L-Ascorbate-1; Vitamin C- 13C6-1) is a 13C labeled L-Ascorbic acid (HY-B0166) . L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
-
- HY-B0166S1
-
|
|
|
L-Ascorbic acid- 13C is the 13C-labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
-
- HY-40136S
-
|
|
|
cis-4-Hydroxy-L-proline-d3 is the deuterium labeled cis-4-Hydroxy-L-proline (HY-40136). cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
|
-
| Cat. No. |
상품명 |
Target |
연구분야 |
Chemical Structure |
-
- HY-B0166GL
-
|
L-Ascorbate (GMP Like); Vitamin C (GMP Like)
|
Reactive Oxygen Species (ROS)
Apoptosis
Calcium Channel
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
|
L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- 상품명:
- Cat. No.:
- 수량:
- MCE Japan Authorized Agent: